MGMT and glioblastoma: These beneficial features might also contribute to the observed median OS of 43 months for the subgroup of non-obese patients with MGMT methylated glioblastoma, comparing favorably to a recent study on the use of immune checkpoint inhibitors in MGMT methylated glioblastoma [19].